S. Dalac‐Rat

Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study)

Nicolas Bertrand, P. Guerreschi, Nicole Basset‐Séguin et al. · EClinicalMedicine · 2021 · 92 citations · Full text

Medicine, Dermatology, Oncology +14

A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6

Brett Hughes, Alexander Guminski, Samantha Bowyer et al. · Journal of the American Academy of Dermatology · 2024 · 59 citations

Medicine, Dermatology, Oncology +15

Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome: A multicentre, retrospective, real‐world French study

M. Beylot‐Barry, G. Quéreux, Charlée Nardin et al. · Journal of the European Academy of Dermatology and Venereology · 2023 · 42 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study).

Laurent Mortier, Nicolas Bertrand, Nicole Basset‐Séguin et al. · Journal of Clinical Oncology · 2018 · 24 citations

Medicine, Dermatology, Oncology +11

Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib

Philippe Saïag, Caroline Robert, Jean‐Jacques Grob et al. · European Journal of Cancer · 2021 · 13 citations · Full text

Medicine, Oncology, Pharmacotherapy +17